Found: 4
Select item for more details and to access through your institution.
Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12505-1
- By:
- Publication type:
- Article
Impact of secondary‐type mutations in NPM1 mutated AML.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 1, p. 165, doi. 10.1111/ejh.13979
- By:
- Publication type:
- Article
TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation.
- Published in:
- Cancers, 2023, v. 15, n. 12, p. 3210, doi. 10.3390/cancers15123210
- By:
- Publication type:
- Article
Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 6, p. 6511, doi. 10.1002/cam4.5421
- By:
- Publication type:
- Article